Generic placeholder image

Pharmaceutical Nanotechnology


ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Research Article

Formulation Optimization and Biopharmaceutical Evaluation of Imatinib Mesylate Loaded β-cyclodextrin Nanosponges

Author(s): Milind Kamble*, Zahid Zaheer*, Santosh Mokale and Rana Zainuddin

Volume 7, Issue 5, 2019

Page: [343 - 361] Pages: 19

DOI: 10.2174/2211738507666190919121445


Background: Many researchers have prepared and evaluated nanosponges and claimed their advantages as an effective drug carrier, especially it was observed prominently in case of anti-fungal drugs. The materials employed to synthesize nanosponges were mainly crosslinking agents, different beta-cyclodextrin and other cellulose-based polymers. Many of them had used ratio proportions of cross-linking agents, d polymers to synthesize these nanosponges which ultimately produce a porous mesh-like network known as nanosponges where actually drug is encapsulated or loaded.

Objective: In the present investigation, we observed the effect of various levels of crosslinking agents and beta-cyclodextrin concentrations on porosity, drug encapsulation, zeta potential and drug release by employing the quality by design approach to synthesize nanosponges rather than merely keeping both concentrations in proportions.

Methods: We have slightly modified the method reported earlier i.e. melting method in which we have used rota evaporator receiver vessel for melting cross-linking agent and beta- cyclodextrin, rotated at 20 RPM at 100°C.

Results: In a quality by design approach, we observed that out of four dependent variables i.e. porosity, drug loading, zeta potential and drug release, three significantly depend on the crosslinking of beta-cyclodextrin molecules which is highly appreciated by the amount of cross-linking agent present in the reaction. The pharmacokinetics of Imatinib loaded optimized nanosponges were compared with the reference product to observe the pattern of absorption and disposition.

Conclusion: Nanosponges synthesized by optimization technique could be effective means of anti-cancer drug oral administration as they encapsulate the drug effectively and offer a prolonged release of drug which gradually releases the drug and avoids unnecessary exposure of the drug.

Keywords: Beta-cyclodextrin, crosslinking agents, drug encapsulation, imatinib mesylate, nanosponges, zeta potential.

Graphical Abstract
Li D, Ma M. Cyclodextrin polymer separation materials. WO9822197 1998.
Trotta F, Cavalli R. Ultrasound assisted synthesis of cyclodextrin based nanosponges. WO0002814A1 2006.
Trotta F, Zanetti M, Cavalli R. Cyclodextrin-based nanosponges as drug carriers. Beilstein J Org Chem 2012; 8: 2091-9.
Trotta F, Cavalli R. Characterization and applications of new hyper-cross-linked Cyclodextrins. Compos Interfaces 2009; 16: 39-48.
Tejashri G, Amrita B, Darshana J. Cyclodextrin based nanosponges for pharmaceutical use: a review. Acta Pharm 2013; 63(3): 335-58.
Sherje AP, Dravyakar BR, Kadam D, Jadhav M. Cyclodextrin-based nanosponges: a critical review. Carbohydr Polym 2017; 173: 37-49.
Shankar S, Pradeep R, Francesco T, et al. Structural evidence of differential forms of nanosponges of beta-cyclodextrin and its effect on solubilization of a model drug. J Incl Phenom Macrocycl Chem 2013; 76: 201-11.
Shankar S, Vavia PR, Francesco T, Satyen T. Formulation of betacyclodextrin based nanosponges of itraconazole. J Incl Phenom Macrocycl Chem 2007; 57: 89-94.
Monica R, Amrita B, Ishwar K, Ghanshyam M, Francesco T. In vitro and in vivo evaluation of b-cyclodextrin-based nanosponges of telmisartan. J Incl Phenom Macrocycl Chem 2012; 12: 224-7.
Darandale S, Vavia P. Cyclodextrin-based nanosponges of curcumin: formulation and physicochemical characterization. J Incl Phenom Macrocycl Chem 2012; 75: 315-22.
Barbara M, Alessandro B, Silvia M, et al. In vitro enhancement of anticancer activity of paclitaxel by a Cremophor free cyclodextrin-based nanosponge formulation. Incl Phenom Macrocycl Chem 2012; 74: 201-10.
Mufassir M, Zahid Z, Rana Z, Jaiprakash N. Extended release delivery of erlotinib glutathione nanosponges for targeting lung cancer. Artif Cells Nanomed Biotechnol 2018; 45(8): 1064-75.
Trotta F, Dianzani C, Caldera F, Mognetti B, Cavalli R. The application of nanosponges to cancer drug delivery. Expert Opin Drug Deliv 2014; 11(6): 931-41.
National Center for Biotechnology Information. Pub- Chem Compound Database; CID=123596,. (accessed Apr. 1, 2018).
Mughal TI, Schrieber A. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biologics 2010; 4: 315-23.
Rao MR, Bhingole RC, Rohini C. Nanosponge-based pediatric-controlled release dry suspension of Gabapentin for reconstitution. Drug Dev Ind Pharm 2015; 41(12): 2029-36.
Moore GE, Gerner RE, Franklin HA. Culture of normal human leukocytes. JAMA 1967; 199(8): 519-24.
Lee Y-L, Chen C-W, Liu F-H, Huang Y-W, Huang H-M. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation. PLoS One 2013; 8(4)e61939
Momin MM, Zaheer Z, Zainuddin R, Sangshetti JN. Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer. Artif Cells Nanomed Biotechnol 2018; 46(5): 1064-75.
Sadat Shandiz SA, Shafiee Ardestani M, Shahbazzadeh D, et al. Novel imatinib-loaded silver nanoparticles for enhanced apoptosis of human breast cancer MCF-7 cells. Artif Cells Nanomed Biotechnol 2017; 45(6): 1-10.
Mehdizadeh M, Rouhani H, Sepehri N, et al. Biotin decorated PLGA nanoparticles containing SN-38 designed for cancer therapy. Artif Cells Nanomed Biotechnol 2017; 45(3): 495-504.
Cho EC, Xie J, Wurm PA, Xia Y. Understanding the role of surface charges in cellular adsorption versus internalization by selectively removing gold nanoparticles on the cell surface with a I2/KI etchant. Nano Lett 2009; 9(3): 1080-4.
Xiao W, Chen WH, Xu XD, et al. Design of a cellular-uptake-shielding “plug and play” template for photo controllable drug release. Adv Mater 2011; 23(31): 3526-30.
Gambacorti-Passerini C, Zucchetti M, Russo D, et al. α1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003; 9(2): 625-32.
Gambacorti-Passerini C, Barni R, le Coutre P, et al. Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000; 92(20): 1641-50.
Shankar S, Pradeep V, Francesco T, et al. Structural evidence of differential forms of nanosponges of beta-cyclodextrin and its effect on solubilisation of a model drug. J Incl Phenom Macrocycl Chem 2013; 76: 201-11.

© 2024 Bentham Science Publishers | Privacy Policy